STOCK TITAN
  1. Home
  2. News
  3. DTCFF

DEFENCE THERAPEUTICS A - $DTCFF STOCK NEWS

Welcome to our dedicated page for DEFENCE THERAPEUTICS A news (Ticker: $DTCFF), a resource for investors and traders seeking the latest updates and insights on DEFENCE THERAPEUTICS A stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DEFENCE THERAPEUTICS A's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DEFENCE THERAPEUTICS A's position in the market.

News
Defence Begins Trading on the OTCQB and Arranges Financing
Rhea-AI Summary
Defence Therapeutics Inc. announces a non-brokered private placement of up to $2,790,000 to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX®. The company's common shares have been upgraded to OTCQB, and are now trading under the symbol 'DTCFF'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Defence's AccuTOX(R) Impairs Lung Cancer Growth
Rhea-AI Summary
Defence Therapeutics Inc. (DTC) successfully tested a new formulation of its ACCUM-002TM Dimer CDCA-SV40, known as AccuTOX®, for lung-established tumors. The drug demonstrated enhanced therapeutic properties and broader application in cancer therapeutics, with successful preclinical studies and FDA clearance to begin a Phase I trial in patients with melanoma. The global cancer therapeutics market size is expected to reach US$393.61 billion by 2032, presenting significant growth opportunities for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
RETRANSMISSION: Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)
Rhea-AI Summary
Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) announces FDA approval for Phase I clinical trial of AccuTOX™, a first-in-class injectable anticancer molecule for solid cancer tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial fda approval
News
Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)
Rhea-AI Summary
Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) has received clearance from the U.S. FDA for its Phase I clinical trial of ACCUM-002TM Dimer CDCA-SV40, also known as AccuTOX®, as an injectable anticancer molecule for the treatment of solid cancer tumors. This marks a significant milestone for Defence in the immune-oncology field, positioning AccuTOX® as the company's flagship asset in the anti-cancer therapeutics field. The approval reflects the company's commitment to addressing unmet clinical needs and becoming a global leader in innovative anti-cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial fda approval
-
News
Defence's Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
Rhea-AI Summary
Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) is pleased to announce the successful submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its ACCUM-002TM Dimer CDCA-SV40, AccuTOX®, an injectable anticancer molecule. The IND application includes preclinical animal testing data, pharmacology, pharmacokinetics, and toxicology studies, and details of drug substance and product manufacturing. The company aims to advance AccuTOX® into a Phase I clinical trial by Q1-Q2 2024. The primary objective of the upcoming trial is to identify the best therapeutic dosing range for co-administration with Opdulag®, a BMS product, in treating patients with solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
News
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
Rhea-AI Summary
Defence Therapeutics Inc., a Canadian biopharmaceutical company, has received a Notice of allowance for its Canadian patent application. The patent covers key vaccine platform technologies that enhance the immunogenicity of protein subunit vaccines, potentially improving their efficacy and lowering antigen dose required. The company already has a counterpart US patent. Defence intends to leverage these patents to secure broad patent protection in other markets and explore licensing and partnering opportunities. The global oncology market is predicted to be worth around $536.01 billion by 2029.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
News
Defence's AccuTOX(R) And Antigen Cross-Presentation: Discovery Leads Towards the Development of a Groundbreaking Platform
Rhea-AI Summary
Defence Therapeutics announces discovery of novel function for AccuTOX® in cancer vaccine engineering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Defence's Novel Accutox(TM) Continues to Surprise on Results Against Cancer
Rhea-AI Summary
Defence Therapeutics announces advancements in AccuTOXTM against cancer and its potential as a future treatment in immune-oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
News
Defence's Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma
Rhea-AI Summary
Defence Therapeutics announces successful study on AccuTOXTM-chitosan encapsulated formulation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.43%
Tags
none
News
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
Rhea-AI Summary
Defence Therapeutics announces publication of peer-reviewed study on anticancer properties of its product Accum®
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
clinical trial
Stock DTCFF logo
DEFENCE THERAPEUTICS A

OTC:DTCFF

DTCFF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

DTCFF Stock Data

50.46M
42.55M
4.73%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Vancouver